reinforcing kidney and activating blood serial recipe, metformin, or their combination for insulin resistance in women with polycystic ovarian syndrome: a double blind randomised controlled trial

注册号:

Registration number:

ITMCTR2000003975

最近更新日期:

Date of Last Refreshed on:

2020-09-23

注册时间:

Date of Registration:

2020-09-23

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

补肾活血方联合二甲双胍治疗胰岛素抵抗型多囊卵巢综合征:随机双盲对照研究

Public title:

reinforcing kidney and activating blood serial recipe, metformin, or their combination for insulin resistance in women with polycystic ovarian syndrome: a double blind randomised controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

补肾活血方联合二甲双胍治疗胰岛素抵抗型多囊卵巢综合征:随机双盲对照研究

Scientific title:

reinforcing kidney and activating blood serial recipe, metformin, or their combination for insulin resistance in women with polycystic ovarian syndrome: a double blind randomised controlled trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

81804136

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000038507 ; ChiMCTR2000003975

申请注册联系人:

杨艺娇

研究负责人:

倪晓容

Applicant:

Yang Yijiao

Study leader:

Ni Xiaorong

申请注册联系人电话:

Applicant telephone:

+86 18701896179

研究负责人电话:

Study leader's telephone:

+86 15102108837

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yijiaoyang123@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

1120@szy.sh.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市静安区芷江中路274号

研究负责人通讯地址:

上海市静安区芷江中路274号

Applicant address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

Study leader's address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

200333

研究负责人邮政编码:

Study leader's postcode:

200333

申请人所在单位:

上海市中医医院

Applicant's institution:

Shanghai Traditional Chinese Medicine Hospital, Shanghai, China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2019SHL-KY-38

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海市中医医院伦理委员会

Name of the ethic committee:

Ethics committee of Shanghai Traditional Chinese Medicine Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

凌丽

Contact Name of the ethic committee:

Ling Li

伦理委员会联系地址:

上海市静安区芷江中路274号

Contact Address of the ethic committee:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市中医医院

Primary sponsor:

Shanghai Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

上海市静安区芷江中路274号

Primary sponsor's address:

274 Zhijiang Middle Road, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

静安区

Country:

China

Province:

Shanghai

City:

Jiang'an

单位(医院):

上海市中医医院

具体地址:

上海市静安区芷江中路274号

Institution
hospital:

Shanghai Traditional Chinese Medicine Hospital

Address:

274 Zhijiang Middle Road, Jing'an District

经费或物资来源:

国家自然科学基金青年项目(81804136)

Source(s) of funding:

National Natural Science Foundation of China (81804136)

研究疾病:

多囊卵巢综合征

研究疾病代码:

Target disease:

polycystic ovarian syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

为了评价二甲双胍单独应用及补肾活血方联合二甲双胍治疗多囊卵巢综合征女性排卵率的疗效。主要假设为补肾活血方联合二甲双胍可比单独治疗提高排卵率。

Objectives of Study:

We aim to determine the efficacy of metformin with or without reinforcing kidney and activating blood serial recipe in achieving ovulation among women with PCOS in Mainland China. The primary hypothesis is that the combination of reinforcing kidney and activating blood serial recipe and metformin results in a significantly higher ovulation rate than metformin or reinforcing kidney and activating blood serial recipe alone.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄在18-40岁之间 (2)符合2003年鹿特丹PCOS国际标准①卵巢排卵障碍表现月经稀发或闭经;②临床或生化测定雄性激素水平升高或临床表现多毛痤疮;③卵巢形态学呈多囊改变。上述3条中符合2条。 (3)符合胰岛素抵抗诊断标准; (4)符合排卵障碍诊断标准; (5)自愿加入,并签署知情同意书者。

Inclusion criteria

1. Aged between 18 and 40 years; 2. Confirmed diagnosis of PCOS according to the Rotterdam 2003 criteria (2 of 3): (1) Oligo-ovulation or anovulation; (2) Clinical and/or biochemical signs of hyperandrogenism; (3) PCOs and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumours and Cushing's syndrome); 3. Confirmed diagnosis of insulin resistance; 4. Confirmed diagnosis of ovulatorydysfunction; 5. join voluntarily and sign an informed consent.

排除标准:

(1)心、肺、肝、肾等重要脏器的疾病; (2)最近3个月内,使用激素或其他药物,包括中药方剂和中成药; (3)最近6周内有怀孕史、流产或生产史; (4)最近6个月有哺乳史。

Exclusion criteria:

1. Patients with known severe organ dysfunction or mental illness; 2. Use of hormonal drugs or other medications including Chinese herbal prescriptions in the past 3 months; 3. Pregnancy, postabortion or postpartum within the past 6 weeks; 4. Breastfeeding within the past 6 months.

研究实施时间:

Study execute time:

From 2020-12-25

To      2022-12-25

征募观察对象时间:

Recruiting time:

From 2020-12-25

To      2022-12-25

干预措施:

Interventions:

组别:

试验组

样本量:

88

Group:

Experimental group

Sample size:

干预措施:

二甲双胍加补肾活血方

干预措施代码:

Intervention:

reinforcing kidney and activating blood serial recipe and metformin

Intervention code:

组别:

对照组

样本量:

88

Group:

Control group

Sample size:

干预措施:

二甲双胍加补肾活血安慰剂

干预措施代码:

Intervention:

Metformin

Intervention code:

样本总量 Total sample size : 176

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

静安

Country:

China

Province:

Shanghai

City:

Jingan

单位(医院):

上海市中医医院

单位级别:

三级甲等

Institution/hospital:

Shanghai Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

促卵泡刺激素

指标类型:

次要指标

Outcome:

Follicle-stimulating hormone (FSH)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素2受体

指标类型:

次要指标

Outcome:

Interleukin-2 receptor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素10

指标类型:

次要指标

Outcome:

Interleukin-10

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素8

指标类型:

次要指标

Outcome:

Interleukin-8

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

排卵率

指标类型:

主要指标

Outcome:

ovulation rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子宫内膜厚度

指标类型:

次要指标

Outcome:

Endometrial thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素1β

指标类型:

次要指标

Outcome:

Interleukin 1 beta

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素6

指标类型:

次要指标

Outcome:

Interleukin-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

小卵泡个数

指标类型:

次要指标

Outcome:

Number of small follicles

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

triglycerides

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白

指标类型:

次要指标

Outcome:

high-density lipoprotein cholesterol (HDL-C)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卵巢体积

指标类型:

次要指标

Outcome:

Ovarian volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胆固醇

指标类型:

次要指标

Outcome:

cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总睾酮

指标类型:

次要指标

Outcome:

Total testosterone (T)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白

指标类型:

次要指标

Outcome:

low-density lipoprotein cholesterol (LDL-C)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促黄体生成素

指标类型:

次要指标

Outcome:

Luteinising hormone (LH)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子α

指标类型:

次要指标

Outcome:

Tumor necrosis factor α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素

指标类型:

次要指标

Outcome:

Fasting insulin concentrations

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

次要指标

Outcome:

Fasting glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

由上海中医药大学负责随机序列号的产生,并将其放入系统中(http://210.76.97.192: 8080/cjbyj)。研究者登录系统后可随机抽号。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomisation will be performed through a webbased randomisation system (http://210.76.97.192: 8080/cjbyj) operated by an independent data centre: Shanghai University of Traditional Chinese Medicine (SHUTCM)

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

根据研究进程择期选择具体方式公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Will be published on Baidu Cloud Netdisk within 6 months after the test is completed

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者根据受试者的原始观察记录,将数据及时完整正确的载入病例报告表,录入采用相应数据库双人双机录入,之后对数据库进行两遍比对。电子数据文件分类保存,并有多个备份保存于不同磁盘和记录介质,防止损坏。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

According to the original observation records of the subjects, the researcher loaded the data into the case report form in a timely, complete and correct manner. The data was entered in the corresponding database using two-person dual-computer entry, and then the database was compared twice. Electronic data files are classified and stored, and multiple backups are stored on different disks and recording media to prevent damage.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above